

# Patient Heal ThyselF.

written by InvestorNews | September 1, 2021

Many, many years ago I worked in the crude oil marketing business with a gentleman (and I use that term loosely) who had a drawer full of “marketing mints”. The so called “mints” ranged from antacids to Tylenol to Advil and various assorted other over the counter remedies for just about anything that ails you. He had a quote that I still use today, “better living through modern chemistry”. Medical science has come a long way over whatever time frame you want to compare and continues to marvel and astound with every new innovation and improvement. Society as a whole is very fortunate for all the really smart people who work hard every day to make our lives better and more comfortable.

Along those lines, today we are going to discuss a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities. [XPhyto Therapeutics Corp.](#) (CSE: XPHY | OTCQB: XPHYF) is a next generation bioscience company whose business activities include: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. It’s like a health and wellness ETF all in one stock.

Similar to many of its peers in this new age of a global pandemic, XPhyto was able to adapt some of its existing IP and pivot towards the development of a rapid point of care COVID-19 RT-PCR diagnostic test. However, the key differentiator for XPhyto is that this 25-minute test is a PCR test, not your typical rapid test. The PCR test is accurate and reliable, and

has become the gold standard test for diagnosing COVID-19. In March of this year, the Company's test was [approved and registered](#) within the European Union as a commercial in vitro diagnostic test. This in turn led to [an agreement](#) with an established German pharmaceutical wholesaler and service provider for the distribution, storage and logistics of XPhyto's diagnostic products in Germany. By the end of May, they had begun the sale of its [25-minute SARS-CoV-2 RT-PCR test system](#) in Germany. And in late June XPhyto announced that [ten COVID-19 test centers](#) in Berlin, Germany had taken delivery of approximately 1,000 tests for the summer and high travel season.

For many countries, only polymerase chain reaction (PCR) tests are accepted to travel making XPhyto's decentralized testing model critical to yield faster results and more versatile test center options. Processing will occur directly at the sample collection site representing a significant shift from conventional PCR testing models whereby samples are collected and then shipped to large centralized and automated labs for processing. So now instead of trying to track down a test facility before your flight home and hoping you get the result before you head out to the airport, all you have to do with XPhyto's test is get to the airport half an hour early and you're good to go.

This is the meat and potatoes stuff going on at XPhyto which could help achieve near term revenue and hopefully help finance the more interesting and exciting developments they have on the go. Those exciting things include the latest announcement by the Company regarding the launch of their [first biosensor test](#). This test for oral inflammation is an easy at home self-check that can be performed without the need for specific medical knowledge or training, analytical equipment or even a power supply. When placed on the tongue, the thin film dissolves and, after 5 minutes, the biosensor releases a bitter taste if oral

inflammation exists. The biosensor functions as a quick test for heightened levels of certain bacteria and viruses to check whether a doctor's visit and further tests are necessary.

In fact, this is the second biosensor announcement in a month. At the end of July, XPhyto and its [soon to be acquired](#) partner 3a-diagnostics reported the breakthrough identification of [COVID-19 biosensor](#) candidates. It's the first saliva activated biosensor molecules identified to diagnose COVID-19 infection using XPhyto's oral dissolvable delivery platform. These enzyme-activated biosensors are developed for real-time, low cost and easy to use oral screening applications for the rapid detection of infectious diseases at home or at the point of care. XPhyto, via 3a, has developed a pipeline of molecular biosensor screening tests for bacterial and viral infectious diseases which include stomatitis, periimplantitis, periodontitis, group A streptococcus, and influenza A. Pretty fascinating stuff, even if I don't know what half of the things they can readily identify even are.

These are just some of the activities going on at XPhyto, other pursuits include work in the psychedelic space with an exclusive development deal with a Canadian University for industrial scale synthesis of pharmaceutical grade Mescaline and an exclusive development deal with German University for industrial scale biotech production of pharmaceutical grade Psilocybin. The Company has a letter of intent for cooperation in the field of development, production, and distribution of new cannabis infused beverages and products with renowned German brewery Oettinger Brauerei GmbH. Through its wholly owned subsidiary, Vektor Pharma TF GmbH, it's planning to build a new commercial drug manufacturing facility in Germany. Hence the ETF comment earlier.

The Company should be well funded for the time being as there

were 3.1 million in the money warrants exercised for \$2.5 million prior to the July 31<sup>st</sup> expiry date. Combined with the \$1.6 million in cash available at the end of Q2 should provide enough liquidity to get to the next quarterly results which will hopefully show some revenue from the rapid COVID-19 PCR tests. The warrant exercise takes the shares outstanding to approximately 72.9 million making for a market cap of roughly \$120 million based on yesterday's close of \$1.65. Let's see if XPhyto Therapeutics provides us with a better living via their modern chemistry.

---

# Mental health at the forefront of new research into Psychedelics

written by InvestorNews | September 1, 2021

The liberalization of cannabis usage (pun intended) has made strides in opening up other aspects of the drug spectrum. To that end, today we are going to look at [Numinus Wellness Inc.](#) (TSXV: NUMI), a leader in health care and research creating psychedelic centered solutions to treat mental illness, substance abuse and trauma.



There has been a paradigm shift in the treatment of mental illness over the last few years. Psychedelics are becoming more accepted, validated by academic and industry research, and recognized by Canadian and US regulators. In 2019 the Imperial

College London and Johns Hopkins opened the world's first psychedelic research centers. In late 2020, Health Canada first approved psilocybin therapy for select patients with terminal illness and then went a step further by proposing a federal regulatory revision to allow controlled psychedelic access outside of clinical trials.

At this point, you may be questioning if I'm on psilocybin (more commonly known as magic mushrooms) or MDMA (also referred to as ecstasy or molly). Obviously, we aren't talking about the street version of these drugs but safe, evidence-based psychedelic assisted therapies. The Numinus Wellness model, which includes psychedelic production, research and clinic care, is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse. Numinus is leading the integration of psychedelic-assisted therapies into mainstream clinical practice, and building the foundation for a healthier society.

The company is broken down into three distinct divisions: Numinus Health – which delivers treatments through clinics and virtual services, with clinics in Vancouver and Montreal; Numinus R&D – which is developing clinical and therapeutic protocols to use in treatments, in collaboration with research partners and regulators; and [Numinus Bioscience](#) – currently developing formulations and methods for therapeutics, using Health Canada licenses, scientific expertise and cutting-edge technology. The company enjoys high barriers to entry, reinforced by IP (intellectual property), proprietary protocols, medical expertise, strategic partnerships and regulatory relationships.

Monday, [the company announced](#) a Phase 1 Clinical Trial of natural psilocybin mushroom extraction prepared at the company lab. The Phase 1 trial, done in partnership with [KGK Science](#),

will enroll human volunteers and assess the safety and psychoactive properties of a Psilocybe mushroom product extracted and formulated at the Numinus Bioscience lab in British Columbia. Successful completion of the landmark trial would result in safety and efficacy data for a natural psilocybin product. The trial supports Canada's leadership in the safe production of a key psychedelic that has shown promise in treating mental health conditions.

Psychedelic therapies are increasingly demonstrating efficacy, from psilocybin relieving major depression with greater efficacy than traditional antidepressants to MDMA for PTSD showing both substantial clinical impact and potential cost-savings of millions of dollars per year. A [recent article](#) suggested the psychedelic drugs market size is projected to reach \$10.75 B by 2027 making this industry one to take note of.

Despite the announcement of its Clinical Trial, it's more likely that the stock was up 19% on big volume over the last three days on news that one of its peers, Mind Medicine Inc. (NEO: MMED | Nasdaq: MNMD), announced it begins trading on the Nasdaq today causing Mind Medicine to rally 89% over the same period. The chatboards are rife with rumors that Numinus will follow suit with its own Nasdaq listing. However, this is not a meme stock. The company recently [closed a \\$40M financing](#), bringing its cash position to \$65M. They have a Phase 1 Clinical Trial, are well capitalized to prove out the science behind their proprietary clinical research and are already generating revenue (albeit not cash flow positive). Numinus is well positioned to grow organically, by acquisition or both.

*Disclosure: The author is long Numinus Wellness (TSXV: NUMI).*

---

# Red Light Holland rides the wave of growth in the relatively new psychedelics industry

written by InvestorNews | September 1, 2021

The psychedelics industry is just starting to grow now from a small base and looks quite likely to follow in the footsteps of the cannabis industry's recent success story. Data Bridge Market Research forecasts that the global psychedelics market will grow [from USD 2.077B in 2019 to USD 6.859B by 2027](#). Looking at these numbers that's a 3.3 times increase in just 7 years. Growing acceptance of psychedelic drugs for treating depression and mental disorders are key factors for the forecast growth.

Psychedelics are the class of hallucinogenic drugs that may be used recreationally or for medical purposes. Their main benefits are in enhancing the sensory perception, elevating mood, and promoting spiritual experiences. Psychedelic drugs can be used in a medical setting to help depression, psychological treatments, palliative care and as an aid to help control the mind to be calm and peaceful.

Psychedelics are legal in the Netherlands, where there are an estimated 100 Smart Shops operating, generating over [US\\$100 million](#) in sales annually. The price for 10 grams of truffles (the maximum amount for a beginner) is between [10 to 15 Euros](#) in Amsterdam. Just recently [Canada approved](#) 17 healthcare professionals to possess and use the psychedelic active

ingredient psilocybin to conduct professional training in psilocybin therapy. The focus is mainly for patients dealing with end-of-life distress, but marks the first step towards legal medicinal psychedelics use in Canada.

[Red Light Holland Corp.](#) (CSE: TRIP) is a leader in this market and is well advanced to benefit from the forecast very strong growth. They recently began selling their premium 'magic truffles' products (psychedelics) in the Netherlands. The Netherlands has a long-standing, established legal magic truffles market. Red Light Holland is currently setting up to further grow, distribute and market a premium brand of magic truffles to the legal recreational market within the Netherlands. They are also focusing on the medicinal side of the psychedelics industry as well as expanding their global sales to legal destinations.

**Red Light Holland's business plan is to produce and sell recreational and medical grade truffle products (psychedelics) in legal markets starting in the Netherlands**



Source: [Company website](#)

Red Light Holland has recently raised over C\$20M, providing the Company with over C\$30M in the bank, this includes the latest [C\\$11.6M bought deal financing](#). The funds intend to be used for working capital and general corporate purposes, essentially to grow the business. Red Light Holland has already grown and pre-sold their first batch of magic truffles from their production facility in Horst, Netherlands. They are now [growing a further 1,000,000 grams](#) of magic truffles. CEO Todd Shapiro [stated](#): "Red Light Holland is ecstatic to announce that we have started to grow our second batch of magic truffles, expected to be 10X the original batch's size."



## **Global and product expansion potential for Red Light Holland**

On February 25, 2021, Red Light Holland [announced](#): “iMicrodose pack receives authorization for the first legal import and sale of psilocybin truffles to Brazil....for prescribed medical patient use.” The iMicrodose pack contains 15g of psilocybin truffles made by Red Light Holland. This marks a significant milestone for Red Light Holland with their “first prescribed by a physician for medical use” of their truffles product, as well as an advancement in opening up the legal and medically approved market for psilocybin in Brazil.

On December 30, 2020, Red Light Holland [announced](#) they intend to make a groundbreaking investment in the St. Vincent and the Grenadines’ plant-based wellness and psychedelics industry, via a purchase of 100% of Mera Life Sciences LLC (‘Mera’). St. Vincent and the Grenadines are islands in the Caribbean Sea. Mera is developing a modern medicinal industry in St Vincent and the Grenadines with their issued psychedelic licenses. Todd Shapiro, CEO and Director of Red Light Holland, stated: “The acquisition of Mera and its coveted licenses would allow Red Light Holland to perform high quality psychedelic product research and development, cultivate, extract and process, and export, not just Psilocybin, but with compounds such as Ayahuasca, MDMA, DMT, Peyote, Ketamine and many other natural based plants as well....”

On December 20, 2020, Red Light Holland [announced](#) it has entered into a non-binding letter of intent to acquire 51% of Psychedelic Insights in Amsterdam, the Netherlands. Psychedelic Insights currently provides psychedelic assistance to clients from all over the world, who are in need and want to try a safe and psychological guided experience. This includes psychedelic palliative care, re-connecting veterans and global mental health screening. A condition in the agreement includes an exclusive

supply agreement with Red Light Holland's truffles, grown from Red Light Holland's facility in Horst, Netherlands.

### **Closing remarks**

Red Light Holland continues to ride a wave of success with their magic truffles psychedelics. A 10x increase in their truffle production following the first batch being 100% pre-sold in advance, an overseas expansion potential via 100% acquisition with Mera, a potential 51% Psychedelic Insights acquisition (global client base), and finally, some initial success selling into Brazil. Added to all this it appears the medicinal use of psychedelics is making progress in Canada.

It certainly looks like Red Light Holland will continue to rapidly grow, especially after their successful capital raises and now C\$30M in the bank. Red Light Holland's market cap has dramatically increased as a result of all this good news and now sits at C\$134M. Exciting times ahead, both for the Company and the industry.

---

**Red Light Holland's Todd Shapiro on investing in a medical and scientific division for the understanding**

# of medical psychedelics

written by InvestorNews | September 1, 2021

“We have named a Science and Innovation division called Scarlett Lillie... We thought that this is a way to show investors how serious we are about our medical, our scientific and research division because not only is Red Light Holland a recreational opportunity, where we plan our products on shelves by Q4, but we also want to show the world that we are taking this side very seriously of trying to prove and being a part of the process of what psilocybin can potentially do for human beings...We want to create this division and grow this division to get involved with observational studies, clinical studies and show the scientific community and be a part of some intellectual property...” States Todd Shapiro, Co-Founder, CEO and Director of [Red Light Holland Corp.](#) (CSE: TRIP), in an interview with InvestorIntel’s Tracy Weslosky.

Todd went on to comment on the appointment of Canada’s former Health Minister, the Honourable, Tony P. Clement, as a Senior Advisor to Red Light Holland’s Advisory Board. Mr. Clement has served in senior roles in Prime Minister Stephen Harper’s Cabinet (2006-2015), as Health Minister, Industry Minister and President of the Treasury Board. Todd also said that Red Light Holland has a strong cash position and is building a very strong team which includes Dr. Joseph Geraci, a leading mind in the medicine and machine learning fields and global comedy superstar, Russell Peters.

To access the complete interview, [click here](#)

Disclaimer: Red Light Holland Corp. is an advertorial member of InvestorIntel Corp.

---

# Todd Shapiro of Red Light Holland on 'magic truffles' and the multi-billion dollar psychedelics market

written by InvestorNews | September 1, 2021

"Psychedelics are a multibillion-dollar market...and that is what this industry is banking on. We are product based, we are a premium brand – the Red Light Truffle will be available in smart shops and we potentially could even have products within the smart shops and on an advanced e-commerce platform by the end of Q3. We plan on setting up a facility that we hope one day will qualify for EU-GMP certification. That means that we can grow a perfect clean room medical grade truffle that could potentially be tested...truffles are sold legally in Netherlands...we think we can capitalize with a premium brand feel and with a micro dose responsible use product." States Todd Shapiro, Co-Founder, CEO and Director of [Red Light Holland Corp.](#) (CSE: TRIP), in an interview with InvestorIntel's Tracy Weslosky.

Todd went on to say that Red Light Holland will have two divisions – Red Light Recreational and Red Light Health. The company is starting with recreational and will have a medical play in the future. Todd also said that Bruce Linton is the Chairman of Red Light Holland's Advisory Board. Bruce is the founder and former CEO of Canopy Growth Corporation. Under his leadership, Canopy Growth was the first cannabis producing company in North America to be listed on a major stock exchange (TSX) and included on a major stock index (S&P/TSX Composite

Index). Canopy Growth was also the first cannabis-producing company to list on the New York Stock Exchange.

To access the complete interview, [click here](#)

Disclaimer: Red Light Holland Corp. is an advertorial member of InvestorIntel Corp.